NasdaqGM - Delayed Quote • USD
Rani Therapeutics Holdings, Inc. (RANI)
At close: April 18 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 3 |
| Avg. Estimate | -0.2 | -0.19 | -0.82 | -0.66 |
| Low Estimate | -0.24 | -0.22 | -1 | -0.82 |
| High Estimate | -0.14 | -0.14 | -0.58 | -0.46 |
| Year Ago EPS | -0.33 | -0.37 | -1.33 | -0.82 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 5 | 5 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.41 | -0.4 | -0.37 | -0.31 |
| EPS Actual | -0.33 | -0.37 | -0.36 | -0.27 |
| Difference | 0.08 | 0.03 | 0.01 | 0.04 |
| Surprise % | 19.50% | 7.50% | 2.70% | 12.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.2 | -0.19 | -0.82 | -0.66 |
| 7 Days Ago | -0.2 | -0.19 | -0.82 | -0.66 |
| 30 Days Ago | -0.31 | -0.29 | -1.11 | -0.83 |
| 60 Days Ago | -0.31 | -0.29 | -1.03 | -0.74 |
| 90 Days Ago | -0.31 | -0.29 | -1 | -0.74 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 4 | 4 | 6 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | RANI | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 39.40% | -- | -- | 0.80% |
| Next Qtr. | 48.60% | -- | -- | 9.60% |
| Current Year | 38.30% | -- | -- | 4.50% |
| Next Year | 19.50% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -9.40% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Canaccord Genuity: Buy to Buy | 3/27/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/25/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 2/6/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/9/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/20/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/8/2023 |
Related Tickers
PROK ProKidney Corp.
2.4000
-15.49%
RZLT Rezolute, Inc.
3.3000
+1.85%
QTTB Q32 Bio Inc.
24.38
+1.08%
ELYM Eliem Therapeutics, Inc.
4.1800
-5.64%
ACRV Acrivon Therapeutics, Inc.
10.54
+1.93%
VIRX Viracta Therapeutics, Inc.
0.9090
-3.55%
FNCH Finch Therapeutics Group, Inc.
2.3600
-6.35%
ENTX Entera Bio Ltd.
2.2400
+0.90%
LYEL Lyell Immunopharma, Inc.
2.3300
-2.10%
CGEM Cullinan Therapeutics, Inc.
18.06
+1.01%